First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Journal:

Nature Medicine

Published:

2026-03-16

DOI:

10.1038/s41591-026-04306-9

Affiliations:

14

Authors:

19

Go to article

Institutions	Authors	Share
Astellas US LLC, United States of America (USA)	6.000000	0.32
National Cancer Center Hospital East, Japan	1.000000	0.05
National Cancer Center Hospital, Japan	1.000000	0.05
IRCCS European Institute of Oncology (IEO), Italy	1.000000	0.05
IRCCS Istituto Oncologico Veneto (IOV), Italy	1.000000	0.05
Seoul National University Bundang Hospital (SNUBH), South Korea	1.000000	0.05
China Medical University Hospital (CMUH), Taiwan	1.000000	0.05
Cancer Institute Hospital, JFCR, Japan	1.000000	0.05
Hôpital Morvan, France	1.000000	0.05
University Hospital of Pisa, UNIPI, Italy	1.000000	0.05
CHU de Bordeaux, France	1.000000	0.05
Seoul National University Hospital (SNUH), South Korea	1.000000	0.05
SIRIC CARPEM, France	1.000000	0.05
Massachusetts General Hospital (MGH), United States of America (USA)	1.000000	0.05

Interested in Oncology and Carcinogenesis?